{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Kyverna Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"KYTX"},"Address":{"label":"Address","value":"5980 HORTON STREET,SUITE 550, EMERYVILLE, California, United States"},"Phone":{"label":"Phone","value":"+1 (510) 626-8331"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases. The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. Kyverna's pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases."},"CompanyUrl":{"label":"Company Url","value":"https://www.kyvernatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Dominic Borie","title":"President-Research & Development"},{"name":"Karen Walker","title":"Chief Technology Officer"},{"name":"Peter Wung","title":"VP & Head-Clinical Development & Operations"},{"name":"Tom van Blarcom","title":"Senior Vice President & Head-Research"},{"name":"Warner Biddle","title":"Chief Executive Officer & Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}